Oniria Therapeutics awarded with the 2023 NEOTEC grant from the Spanish Ministry of Science and Innovation to develop new drugs that overcomes colon cancer persistence

Oniria Therapeutics has been selected for the NEOTEC 2023 program of the Centre for the Development of Industrial Technology (CDTI) —a public entity under the Ministry of Science, Innovation and Universities of Spain— with a grant of €335,000.

The funding will allow the biopharmaceutical company the execution of their business plan towards the development of new drugs  based on modulation of cellular latency to overcome colon cancer persistence.

NEOTEC is one of the most prestigious grants awarded by the Ministry of Science, Innovation and Universitites and aims to support the creation and consolidation of technology-based companies. In this year’s call, among 371 applications only 131 were selected.